Linked Life Data

17187388

Source:http://linkedlifedata.com/resource/pubmed/id/17187388

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-2-15
pubmed:abstractText
Conflicting findings with regard to the teratogenic risks of first trimester use of paroxetine have prompted the FDA, Health Canada, and the manufacturer of the drug to issue warnings against its use during pregnancy. Given that untreated depression during pregnancy can lead to deleterious effect on the mother and her unborn fetus, data on the relationship between the dose and the range of malformations is warranted. This study attempts to quantify the association between first trimester exposure to paroxetine and congenital cardiac malformations, adjusting for possible confounders, and to quantify the dose-response relationship between paroxetine use and cardiac defects.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1542-9733
pubmed:author
pubmed:copyrightInfo
(c) 2006 Wiley-Liss, Inc.
pubmed:issnType
Print
pubmed:volume
80
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
18-27
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage.
pubmed:affiliation
Faculty of Pharmacy, University of Montreal, Montreal, Québec, Canada. anick.berard@umontreal.ca
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't